Conv. Plasma
Nigella Sativa
Nitric Oxide
Peg.. Lambda

Home   COVID-19 treatment studies for Favipiravir  COVID-19 treatment studies for Favipiravir  C19 studies: Favipiravir  Favipiravir   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Mortality -200% Improvement Relative Risk Ventilation -200% Hospitalization time -20% no CI Recovery 58% Recovery (b) -46% Recovery time 43% no CI Recovery time (b) -15% no CI Time to viral- 47% primary Finberg et al. Favipiravir for COVID-19 RCT LATE Is late treatment with favipiravir beneficial for COVID-19? RCT 50 patients in the USA Faster viral clearance with favipiravir (p=0.042) Finberg et al., Open Forum Infectious Diseases, doi:10.1093/ofid/ofab56310 Favors favipiravir Favors control
US201 Study: A Phase 2, Randomized Proof-of-Concept Trial of Favipiravir for the Treatment of COVID-19
Finberg et al., Open Forum Infectious Diseases, doi:10.1093/ofid/ofab56310
Finberg et al., US201 Study: A Phase 2, Randomized Proof-of-Concept Trial of Favipiravir for the Treatment of COVID-19, Open Forum Infectious Diseases, doi:10.1093/ofid/ofab56310
Dec 2021   Source   PDF  
  All Studies   Meta
Small very late treatment RCT in the USA, with 25 favipiravir and 25 control patients, showing faster viral clearance with treatment. The benefit was only seen in patients <8 days from symptom onset. There were no significant differences in clinical outcomes. The death in the favipiravir group occurred after discharge and was believed to be unrelated to COVID-19 or favipiravir.
risk of death, 200.0% higher, RR 3.00, p = 1.00, treatment 1 of 25 (4.0%), control 0 of 25 (0.0%), continuity correction due to zero event (with reciprocal of the contrasting arm).
risk of mechanical ventilation, 200.0% higher, RR 3.00, p = 1.00, treatment 1 of 25 (4.0%), control 0 of 25 (0.0%), continuity correction due to zero event (with reciprocal of the contrasting arm).
hospitalization time, 19.8% higher, relative time 1.20, treatment 25, control 25.
risk of no recovery, 58.1% lower, OR 0.42, p = 0.08, treatment 25, control 25, inverted to make OR<1 favor treatment, day 8 mid-recovery, 6-point ordinal scale, RR approximated with OR.
risk of no recovery, 46.2% higher, OR 1.46, p = 0.54, treatment 25, control 25, inverted to make OR<1 favor treatment, day 15, 6-point ordinal scale, RR approximated with OR.
recovery time, 42.9% lower, relative time 0.57, treatment 25, control 25, median time to aggregate NEWS2 score ≤2 or discharge.
recovery time, 15.4% higher, relative time 1.15, treatment 25, control 25.
time to viral-, 46.7% lower, relative time 0.53, p = 0.04, treatment 25, control 25, primary outcome.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Finberg et al., 7 Dec 2021, Randomized Controlled Trial, USA, peer-reviewed, 10 authors, average treatment delay 8.4 days.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperFavipiravirAll
Abstract: Open Forum Infectious Diseases MAJOR ARTICLE US201 Study: A Phase 2, Randomized Proof-of-Concept Trial of Favipiravir for the Treatment of COVID-19 Robert W. Finberg,1 Madiha Ashraf,2 Boris Julg,3 Folusakin Ayoade,4 Jai G. Marathe,5 Nicolas C. Issa,6 Jennifer P. Wang,1 Siraya Jaijakul,2 Lindsey R. Baden,6 and Carol Epstein7 1 University of Massachusetts Chan Medical School, Worcester, Massachusetts, USA, 2Houston Methodist Research Institute, Houston, Texas, USA, 3Ragon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology, and Harvard University, Cambridge, Massachusetts, USA, 4University of Miami Miller School of Medicine, Miami, Florida, USA, 5Department of Medicine, Boston University School of Medicine, Boston, Massachusetts, USA, 6Brigham and Women’s Hospital and Harvard Medical School, Boston, Massachusetts, USA, and 7FUJIFILM Pharmaceuticals USA, Inc., Cambridge, Massachusetts, USA Favipiravir, a nucleoside analog, is active against a broad spectrum of RNA viruses. The drug directly interacts with viral polymerases to inhibit viral RNA transcription without affecting host polymerases. A major advantage of this drug is that it can be orally administered and sustainable serum levels achieved. Over 40 clinical trials for favipiravir have been conducted, and it is licensed in Japan to treat influenza virus that is unresponsive to other agents. In influenza studies, in vitro treatment with favipiravir leads to inaccurate transcription of the virus, resulting in virus extinction via the accumulation of multiple detrimental mutations. Such “mutational meltdown” means that escape mutants Received 13 October 2021; editorial decision 25 October 2021; accepted 1 November 2021; published online 7 December 2021. Correspondence: Jennifer Wang, MD, University of Massachusetts Medical School, Department of Medicine, Diabetes Center of Excellence, ASC 7-2047, 368 Plantation St., Worcester, MA 01605 ( Open Forum Infectious Diseases®2021 © The Author(s) 2021. Published by Oxford University Press on behalf of Infectious Diseases Society of America. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (, which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited. are unlikely to occur and has been demonstrated in both in vitro and in vivo studies with influenza [1, 2]. Importantly, in vivo and in vitro studies with influenza indicate that favipiravir does not select for resistant strains. Several studies indicate that favipiravir-ribofuranosyl5’triphosphate (favipiravir-RTP) can be used against SARSCoV-2. Favipiravir has been shown to inhibit replication of SARS-CoV-2 both in vitro and in a hamster model of infection [3, 4]. The drug binds to the SARS-CoV-2 RNA-dependent RNA polymerase [5–7] and suppresses viral replication by inhibiting the incorporation of natural nucleosides [5]. In vitro studies demonstrate that favipiravir binds to the SARS-CoV-2 polymerase and could mimic adenine and guanine [6], suggesting that its mechanism of action in inhibiting SARS-CoV-2 is analogous to the way it inhibits influenza. In addition, by affecting transcription fidelity, favipiravir appears to act on SARS-CoV-2 by generating mutations that are disadvantageous to the virus, possibly leading to “mutational..
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop